Merck Entered into a Multi-Year Strategic Research Collaboration with Cerevance to Discover Novel Targets Using NETSseq Technology for Alzheimer’s Disease
Shots:
- Cerevance to receive a $25M up front & is eligible to receive ~$1.1B in development & commercial milestones along with royalties on sales of approved products that emerge from the collaboration
- The collaboration will use Cerevance's NETSseq technology platform to identify novel targets for AD. Additionally, Cerevance will out-license one discovery-stage program to Merck
- Cerevance's NETSseq technology platform has isolated & enabled for investigation of specific cell populations in the post-mortem, healthy & sick human brain tissue samples across a range of ages & brain regions. The platform also identifies new therapeutic targets to improve neuronal circuitry or decrease the progression of the disease
Ref: Cerevance | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.